PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies

Published:2022 Issue:3 Volume:33 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Miller Rowan E¹²^ORCID,El-Shakankery Karim H¹^ORCID,Lee Jung-Yun³^ORCID

Affiliation:

1. Department of Medical Oncology, University College London Hospital, London, UK.

2. Department of Medical Oncology, St Bartholomew’s Hospital, London, UK.

3. Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2022.33.e44

Reference87 articles.

1. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

2. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

3. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

4. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

5. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pixantrone as a novel MCM2 inhibitor for ovarian cancer treatment;European Journal of Pharmacology;2024-09

2. A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer;Pharmaceutics;2024-08-24

3. PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex;British Journal of Cancer;2024-06-12

4. Oncogenic Pathways and Targeted Therapies in Ovarian Cancer;Biomolecules;2024-05-15

5. Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients;Journal of Experimental & Clinical Cancer Research;2024-05-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3